Skip to content

BODISEN BIOTECH, INC

Delisted

CIK 1178552fmd_0TNB7W84QDR87ZSMV4J56JCKCEManufacturing · Agricultural ChemicalsTemplate: Standard

Coverage: Jan 01, 2010 to Jun 30, 2013, 12 periods

Latest annual · FY2012

Millions
Gross profit
1
Operating income
(14)
Net income
(16)
Free cash flow
(2)

Latest quarter · Q2 FY2013

Millions
Gross profit
0
Operating income
(1)
Net income
(1)
Free cash flow
(0)
Open Financials

BODISEN BIOTECH, INC financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2012FY2011ChangeSource
Gross profit$1.1 million$2.1 million-46.4%10-K 2013-04-16 · proof
Operating income-$13.5 million-$2.3 million10-K 2013-04-16 · proof
Net income-$16.4 million-$2.3 million10-K 2013-04-16 · proof
Cash from operating activities-$2.1 million-$2.8 million10-K 2013-04-16 · proof
Free cash flow-$2.1 million-$2.8 million10-K 2013-04-16 · proof
Total assets$22.7 million$36.9 million-38.6%10-K 2013-04-16 · proof
Total liabilities$2.8 million$2.8 million+1.2%10-K 2013-04-16 · proof
Cash and cash equivalents$294,539$935,375-68.5%10-K 2013-04-16 · proof
What was BODISEN BIOTECH, INC's gross profit in fiscal 2012?
BODISEN BIOTECH, INC reported gross profit of $1.1 million for fiscal 2012 (the year ended Dec 31, 2012), against $2.1 million the year before (-46.4%). Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What was BODISEN BIOTECH, INC's operating income in fiscal 2012?
BODISEN BIOTECH, INC reported operating income of -$13.5 million for fiscal 2012 (the year ended Dec 31, 2012), against -$2.3 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What was BODISEN BIOTECH, INC's net income in fiscal 2012?
BODISEN BIOTECH, INC reported net income of -$16.4 million for fiscal 2012 (the year ended Dec 31, 2012), against -$2.3 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What was BODISEN BIOTECH, INC's cash from operating activities in fiscal 2012?
BODISEN BIOTECH, INC reported cash from operating activities of -$2.1 million for fiscal 2012 (the year ended Dec 31, 2012), against -$2.8 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What was BODISEN BIOTECH, INC's free cash flow in fiscal 2012?
BODISEN BIOTECH, INC reported free cash flow of -$2.1 million for fiscal 2012 (the year ended Dec 31, 2012), against -$2.8 million the year before. Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What are BODISEN BIOTECH, INC's total assets?
As of Dec 31, 2012, BODISEN BIOTECH, INC reported total assets of $22.7 million, against $36.9 million a year earlier (-38.6%). Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What are BODISEN BIOTECH, INC's total liabilities?
As of Dec 31, 2012, BODISEN BIOTECH, INC reported total liabilities of $2.8 million, against $2.8 million a year earlier (+1.2%). Source: the 10-K filed with the SEC on Apr 16, 2013. SEC
What are BODISEN BIOTECH, INC's cash and cash equivalents?
As of Dec 31, 2012, BODISEN BIOTECH, INC reported cash and cash equivalents of $294,539, against $935,375 a year earlier (-68.5%). Source: the 10-K filed with the SEC on Apr 16, 2013. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1178552&period_type=annual&limit=5"

Information only, not investment advice.